Apimeds Pharmaceuticals US, Inc. (APUS) Form 8-K — May 5, 2026
Apimeds Pharmaceuticals US, Inc. appointed Sungjoon Chae as Co-Chief Executive Officer effective May 4, 2026, following a stockholder nomination. Mr. Chae is an architect and urban designer with a Master of Architecture in Urban Design from Harvard University, bringing experience in real estate development rather than the pharmaceutical industry.
Price after filing
1 day: -35.0%7 days: -55.3%30 days: -53.0%
Close on the filing date to close N calendar days later (from $3.00). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.